The SIR-POBA Bypass Trial
SIRrolimus-coated Versus Plain Old Balloon Angioplasty (POBA) in Lower Extremity Autologous Venous Bypass Stenosis - The SIR-POBA Bypass Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Salzburg, Austria, 5020
- University Hospital of Salzburg, Paracelsus Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age at least 18 years
- Informed consent with signature
- Rutherford category 2 or 3 (in terms of lifestyle-limiting moderate or severe claudication symptomatology) or chronic critical ischemia (Rutherford 4-6)
- Venous bypass stenosis requiring intervention
- Confirmed inflow
- At least 1 crural outflow vessel
Exclusion Criteria:
- Pregnant or lactating women
- Active infection or sepsis
- Patients currently participating in another clinical trial
- Unconfirmed inflow
- Intolerance to sirolimus
- Coagulopathy
- Radiotherapy
- Patients on immunosuppressive therapy
- Non-dialysis renal insufficiency (eGFR < 45 ml/min/1.73m2)
- Use of potent CYP3A4 and/or P-gp inhibitors (such as ketoconazole, Voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong CYP3A4 and/or P-gp inducers (such as rifampin or rifabutin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Plain Balloon Angioplasty
Plain Balloon Angioplasty will be used to treat lesions
|
Revascularisation procedures will be performed according to randomised list
Other Names:
|
|
Active Comparator: Sirolimus-coated Balloon Angioplasty
Sirolimus-coated Balloon Angioplasty will be used to treat lesions after preparing vessel with plain balloon angioplasty
|
Revascularisation procedures will be performed according to randomised list
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Primary Lesion Target Patency of the venous bypass stenosis
Time Frame: 2 years
|
The incidence of patency will be analysed after reopening the stenosis of the venous bypass.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Stephanie Rassam, MD, Resident Physician
- Principal Investigator: Manuela Pilz, MD PD FEBVS, Senior Physician
- Study Director: Klaus Linni, MD PD FEBVS, Head of Division of Vascular and Endovascular Surgery
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1036/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.